Shots:
- Health Canada has approved label expansion of Evkeeza, as an adjunct to diet & other lipid-lowering therapies, to treat children (≥6mos.) with HoFH
- Approval was based on model-based analysis that predicted similar or greater LDL-C reductions with Evkeeza (15mg/kg, Q4W) in children (6mos. to 5yrs.) at 24wks. Data from compassionate use in 5 children (1-4yrs.) depicted meaningful LDL-C reduction, consistent with older pediatric pts (≥5yrs.)
- Evkeeza is reimbursed & commercially available in Canada via private drug plans, along with Quebec, UK, US, Italy, Japan, Netherlands, Spain & Luxembourg via public drug plans, with early access in 13 other regions incl. Austria & France
Ref: Globenewswire| Image: Ultragenyx| Press Release
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
